NEW YORK, Dec. 8, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline, and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that Dr. Daniel Chain, Ph.D., Chairman and CEO, will deliver a speech at the Center for Business Intelligence ("CBI") 4th Annual Alzheimer's Drug Development Summit to be held December 14-15, 2010, at the DoubleTree Hotel in Washington D.C. Dr. Chain's speech, "Unique Molecular Signatures of Amyloid Beta as Targets for Therapy", will provide an overview of two different approaches to Alzheimer's treatment: Immunotherapy using highly specific monoclonal antibodies and treating AD with drugs that prevent copper-mediated neurotoxicity. Intellect's drug development pipeline includes drug candidates that utilize these approaches.
